Aurora, Colorado, USA, November 12, 2026
University of Colorado Anschutz Medical Campus has reported important findings from a long-term follow-up analysis of the landmark COURAGE clinical trial, providing new insights into the long-term effectiveness of coronary artery stenting in patients with stable coronary artery disease. The research found that an initial treatment strategy involving percutaneous coronary intervention (PCI), commonly known as angioplasty, and stent placement, combined with optimal medical therapy, did not significantly reduce the long-term risk of death or heart attack compared with optimal medical therapy alone. Led by Neel Butala, MD, a researcher at CU Anschutz, the analysis examined patient outcomes over an extended period, with some participants followed for as long as 25 years. The findings were published in the prestigious medical journal JAMA and presented at the 2026 American Heart Association (AHA) Scientific Sessions. The research addresses an important question in cardiovascular medicine: whether mechanically opening narrowed coronary arteries provides additional long-term protection against heart attacks and death beyond the benefits achieved through medication and other established medical treatments.
25-Year COURAGE Trial Follow-Up Reveals Key Findings
The original COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial compared two treatment approaches for individuals with stable coronary artery disease. One group received PCI alongside optimal medical therapy, while the other received optimal medical therapy alone. PCI involves using a balloon catheter to widen narrowed coronary arteries, often followed by the placement of a small metal stent to maintain blood flow. For the latest analysis, researchers evaluated long-term outcomes among 959 participants from the original trial, using linked healthcare records to assess mortality and heart attack events. The median follow-up period was approximately 15 years, with some patients followed for up to 25 years. The results demonstrated no statistically significant difference in the combined risk of death or heart attack between the two treatment groups. The estimated 25-year cumulative incidence of death or heart attack was 93.3% among patients initially assigned to PCI plus medical therapy, compared with 91% among those assigned to medical therapy alone. These findings provide additional long-term evidence that an initial invasive treatment strategy does not necessarily translate into improved survival or reduced heart attack risk for patients with stable coronary artery disease. The analysis also expands previous COURAGE research by incorporating heart attack outcomes alongside long-term survival data.
Stents Continue to Play an Important Role in Symptom Relief
The study findings do not suggest that coronary stents or angioplasty are unnecessary. Instead, they highlight the importance of distinguishing between improving blood flow and preventing future cardiovascular events. Coronary stenting can effectively open narrowed arteries and improve blood circulation, helping patients experience relief from chest pain, also known as angina, and other symptoms associated with coronary artery disease. For certain patients, these procedures can significantly improve quality of life by reducing symptom burden and supporting daily activities. Additionally, emergency coronary interventions remain essential and can be lifesaving for individuals experiencing specific types of acute heart attacks. However, the latest findings suggest that for patients with stable coronary artery disease, opening a blocked artery through an initial PCI procedure does not automatically provide additional protection against future heart attacks or death compared with medical treatment alone. Optimal medical therapy remains a critical component of cardiovascular disease management, involving appropriate medications, risk-factor management and lifestyle modifications. The research therefore reinforces the importance of evaluating treatment decisions according to individual patient conditions, symptoms and long-term clinical objectives rather than focusing exclusively on the technical success of a procedure.
Long-Term Evidence Supports Individualised Heart Care
The research provides valuable information for cardiologists, healthcare professionals and patients making decisions about the management of stable coronary artery disease. The investigators also acknowledged important study limitations. The latest analysis was a post hoc observational follow-up of participants from the original randomised COURAGE trial, rather than a newly conducted randomised clinical trial. The analysis included veterans whose healthcare records could be linked to the original study, representing a population with higher baseline health risks than the broader original trial population. Researchers also noted that identifying heart attacks through routinely collected healthcare records has certain limitations, although the findings were consistent with independently verified events from the original trial. Despite these considerations, the extended follow-up provides valuable evidence about cardiovascular outcomes over an unusually long period. The findings emphasise the need for personalised treatment strategies that consider symptom severity, cardiovascular risk factors and the potential benefits and limitations of available interventions. The 25-year COURAGE follow-up strengthens the evidence base for shared decision-making in cardiovascular care, helping clinicians and patients better understand when invasive procedures may be appropriate and when medical therapy can be an effective initial approach. The research represents an important contribution to long-term cardiovascular outcomes research and may help guide future clinical practice and treatment discussions for people living with stable coronary artery disease.
Source: University of Colorado Anschutz press release



